Cytokinetics brings patent suit against Bristol Myers Squibb, escalating rivalry

Cytokinetics sued Bristol Myers Squibb to invalidate a patent on Camzyos, claiming it unfairly targets its rival heart drug Myqorzo (aficamten).

Raccontata daendpoints.news